BioMidwest

Found 69,311 articles

• NIH and PhysIQ Complete Initial Phase of COVID-19 Digital Biomarker Development; Pen Contract for Phase II

  1/19/2021

  The National Cancer Institute (NCI) and the National Institute of Biomedical Imaging and Bioengineering (NIBIB) of the National Institutes of Health (NIH), exercised their option to enter Phase II of a multi-phase contract to continue physIQ’s development of an AI-based COVID-19 digital biomarker to address the rapid decompensation of high-risk COVID-19 patients.

• Viveve Announces Closing of an Upsized $27.6 Million Underwritten Public Offering and Exercise of Over-Allotment Option

  1/19/2021

  Viveve Medical, Inc., a medical technology company focused on women's intimate health, announced the closing of an upsized underwritten public offering of units for gross proceeds of approximately $27.6 million, which includes the exercise of the underwriter's over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses payable by Viveve.

• Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 19, 2021

  1/19/2021

  Revance Therapeutics, Inc., a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product, DaxibotulinumtoxinA for Injection, announced new hire grants totaling an aggregate of 75,400 inducement restricted stock awards to 15 employees.

• Spelman College and IDEAYA Biosciences Announce Partnership for Professional Development of the Next Generation of Female African American Leaders in the Biotechnology Industry

  1/19/2021

  Spelman College and IDEAYA Biosciences, Inc. announce partnership for professional development of the next generation of female African American leaders in the biotechnology industry through the Spelman College and IDEAYA Biosciences Health Science and Biotechnology Program.

• HTG Announces Board of Directors TransitionTimothy Johnson to Retire from the Board; Ann Hanham, Ph.D. Remains Lead Independent Director

  1/19/2021

  HTG Molecular Diagnostics, Inc., a life science company whose mission is to advance precision medicine, announced that Timothy B. Johnson has resigned his positions as Executive Chairman and a member of HTG’s Board of Directors.

• New Vaccination Cart from Ergotron Supports COVID-19 Vaccine Distribution Inside and Outside of Clinics

  1/19/2021

  Ergotron, a global company focused on improving how people work, learn, play and care for others, announced the introduction of a Vaccination Cart to support safe and efficient COVID-19 vaccine distribution.

• ARUP Sequencing Specimens Positive for SARS-CoV-2 to Detect the UK Variant and Other Possible Strains of the Virus

  1/19/2021

  ARUP Laboratories, a major provider of COVID-19 molecular diagnostic testing in Utah and nationwide, announced that it is sequencing variants of SARS-CoV-2 in specimens positive for COVID-19 to enable detection of the more contagious "United Kingdom variant" of the virus.

• OrthoPediatrics Corp. Introduces Expanded Product Portfolio in Canada

  1/19/2021

  OrthoPediatrics Corp., a company exclusively focused on advancing the field of pediatric orthopedics, has obtained 14 product registrations in Canada over the past 12 months.

• byACRE, Medline Announce North American Launch of World's Lightest Rollator

  1/19/2021

  Medline and byACRE, a Copenhagen-based designer and producer of advanced mobility products, announced a strategic partnership to meet the growing demand for stylish and functional mobility aids.

• NHI Prices Offering of Senior Notes - Jan 19, 2021

  1/19/2021

  National Health Investors, Inc. announced that it priced an offering of $400 million aggregate principal amount of 3.00% Senior Notes due 2031.

• Henry Ford Cancer Institute Set to Begin Patient Care at Brigitte Harris Cancer Pavilion

  1/19/2021

  The new 187,000-square-foot facility offers the most advanced cancer treatment options available, convenient access to clinical trials

• Cryoport Announces Proposed Public Offering of Common Stock - Jan 19, 2021

  1/19/2021

  Cryoport, Inc., a global leader in temperature-controlled supply chain solutions for the life sciences industry, announced that it intends to offer $200 million of shares of common stock in an underwritten public offering.

• Pioneer in Robotic Joint Replacement Surgery Joins World #1 in Orthopedics at HSS Florida

  1/19/2021

  Martin W. Roche, MD, who performed the world's first sensor and robotic assisted knee surgery, has joined HSS Florida in West Palm Beach.

• ISM® Reports Economic Improvement to Continue in 2021

  1/19/2021

  Manufacturing Growth Expected in 2021; Revenue to Increase 6.9%; Capital Expenditures to Increase 2.4%; Capacity Utilization Currently at 85.7%; Services Growth Projected in 2021; Revenue to Increase 1.6%; Capital Expenditures to Increase 12.7%: Capacity Utilization Currently at 86.6%

• Celcuity to Present at the B. Riley Oncology Investor Conference

  1/19/2021

  Celcuity Inc. (Nasdaq: CELC), a clinical stage biotechnology company utilizing its 3 rd generation companion diagnostics to identify new targeted therapeutic options for cancer patients, announced today that Brian Sullivan, Chairman, Chief Executive Officer, and Co-Founder of Celcuity, will present at the B. Riley Oncology Investor Conference to be held January 20-21, 2021. Mr. Sullivan will present an overview of Celc

• Cardiovascular Systems, Inc. Receives CE Mark for Diamondback 360® Coronary Orbital Atherectomy System

  1/18/2021

  Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that it has received CE Mark for its Diamondback 360® Coronary Orbital Atherectomy System (OAS) and ViperWire Advance® Coronary Guide Wire with Flex Tip

• Vireo Health Appoints Victor E. Mancebo to Board of Directors

  1/18/2021

  Vireo Health International Inc., ("Vireo" or the "Company") (CNSX: VREO, OTCQX: VREOF), the leading physician-founded, science-focused multi-state cannabis company, today announced the appointment of Victor E. Mancebo to its Board of Directors.

• St. Vincent Home for Children Names New Director of Programs

  1/18/2021

  The St. Vincent Home for Children Board of Trustees and executive leadership team have announced it has hired James Keeton as its Director of Programs. Mr. Keeton joined the agency on January 11, 2021.

• Zomedica CEO Issues Shareholder Letter as TRUFORMA™ Nears Commercialization

  1/18/2021

  Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today issued the following letter from Robert Cohen, Chief Executive Officer, updating Zomedica’s shareholders regarding several key activities and events:

• Genus plc Provides Update on Financial Performance for First Half of Fiscal 2021

  1/18/2021

  Global biotechnology leader in animal genetics reports continued strong performance for the six-months period ending December 31, 2020.